Skip to main content
SpringerLink
Log in

Meloxicam: A toxicology overview

  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

Meloxicam is a new potent non-steroidal anti-inflammatory drug (NSAID), which in animal tests exhibits potential antiarthritic action and has a wider spectrum of anti-inflammatory activity than currently available NSAIDs. Toxicological testing of meloxicam in animals suggests that acute oral overdosage is unlikely to cause severe toxicity in man. Compared with other NSAIDs, meloxicam has a relatively weak effect on gastric acid secretion and on ulceration in the rat stomach. Whereas most NSAIDs can cause parenchymal kidney damage in animals at low plasma levels and over relatively short periods, meloxicam only induces such damage in the rat over the longer term. Meloxicam preferentially inhibits cyclooxygenase-2 (COX-2), rather than cyclooxygenase-1 (COX-1), which may explain its good gastric and renal tolerability. Meloxicam was chondroneutral in long-term studies in rats and mice. It was significantly less phototoxic in vitro than diclofenac, ketoprofen and naproxen, but similar to piroxicam and tenoxicam. There was no evidence of mutagenic, clastogenic, teratogenic or tumorigenic activity on immunogenic potential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vane JR. Towards a better aspirin. Nature. 1994;367:215–16.

    Article  PubMed  CAS  Google Scholar 

  2. Engelhardt G. Meloxicam: A potent inhibitor of COX-2. Abstract presented at the 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, 6–10 June. 1994:82.

  3. Goodwin JS, Ceuppens JL Effect of nonsteroidal antiinflammatory drugs on immune function. Semin Arthritis Rheum. 1983;13(1)(Suppl 1):134–43.

    Article  PubMed  CAS  Google Scholar 

  4. Magnusson B, Kligman AM. The identification of contact allergens by animal assay. The guinea pig maximization test. J Invest Dermatol. 1969;52:268–76.

    PubMed  CAS  Google Scholar 

  5. Hurtenbach U, Gleichmann H, Nagate N, Gleichmann E. Immunity of D-penicillamin, genetic, cellular, and chemical requirements for induction of popliteal lymph node enlargement in the mouse. J Immunol. 1987;139:411–16.

    PubMed  CAS  Google Scholar 

  6. Figueiredo A, Teixeira E, Poiares-Baptista A. Photosensitivity to nonsteroidal anti-inflammatory drugs. Int J Dermatol. 1989;28:139–40.

    Article  Google Scholar 

  7. Kochevar IE. Phototoxicity of nonsteroidal anti-inflammatory drugs. Coincidence or specific mechanism? Arch Dermatol. 1989;125:824–6.

    Article  Google Scholar 

  8. Schmid J, Busch U, Trummlitz G, Prox A, Kaschke S, Wachsmuth H. Meloxicam (UH-AC 62 XX): metabolic pattern and structure elucidation in rats. Xenobiotica. 1995;25:1219–36.

    Article  PubMed  CAS  Google Scholar 

  9. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. Meloxicam: Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos. 1995;23:1206–13.

    PubMed  CAS  Google Scholar 

  10. Kochevar IE, Morison WL, Lamm JL, McAuliffe DJ, Western A, Hood AF. Possible mechanism of piroxicam-induced photosensitivity. Arch Dermatol. 1986;122:1283–7.

    Article  PubMed  CAS  Google Scholar 

  11. Rainsford KD. Concepts of the mode of action and toxicity of anti-inflammatory drugs. A basis for safer and more selective therapy, and for future developments In: Rainsford KD, Velo GP, eds. New developments in antirheumatic therapy, Vol. III. Lancaster: Kluwer Academic Publishers; 1989:37–92.

    Google Scholar 

  12. Dingle JT. NSAIDs and human cartilage metabolism. In: Rainsford KD, Velo GP, eds. Side-effects of Anti-inflammatory Drugs 3: Inflammation and Drug Therapy Series, Vol. V. Dordrecht: Kluwer Academic Publishers; 1992:261–8.

    Google Scholar 

  13. Davis MA, Ettinger WH, Neuhaus JM, Mallon KP. Knee osteoarthritis and physical functioning: Evidence from the NHANES I Epidemiologic Follow up Study. J Rheumatol. 1991;18(4):591–8.

    PubMed  CAS  Google Scholar 

  14. Kohatsu ND, Schurman DJ. Risk factors for the development of osteoarthritis of the knee. Clin Orthop. 1990;261:242–6.

    PubMed  Google Scholar 

  15. Van Der Kraan PM, Vitters EL, Van De Putte LBA, Van Den Berg WB. Development of osteoarthritic lesions in mice by ‘metabolic’ and ‘mechanical’ alterations in the knee joints Am J Pathol. 1989;135:1001–14.

    PubMed  Google Scholar 

  16. Rainsford KD, Ying C, Gadd S, Ginsburg I. Comparative effects of meloxicam on cellular components of joint injury in vitro. Presented at the 2nd International Congress of the Osteoarthritis Research Society (OARS), Orlando, Florida, USA, 9–11 December, 1994.

  17. Engelhardt G. Meloxicam: Comparison of in vitro and in vivo activity. Abstract presented at XVII ILAR Congress of Rheumatology, Rio de Janeiro, Brazil, September 17–23, 1989.

  18. Engelhardt G, Homma D, Schnitzler C. Meloxicam: A potent inhibitor of adjuvant arthritis in the rat. Inflamm Res. 1995;44:548–55.

    Article  PubMed  CAS  Google Scholar 

  19. Wiseman EH. Review of preclinical studies with piroxicam: Pharmacology, pharmacokinetics and toxicology. In: Royal Society of Medicine, International Congress and Symposium Series No. 1. Academic Press Inc (London) and Royal Society of Medicine; 1978:1–23.

  20. Crowshaw K. Role of inhibition of prostaglandin biosynthesis by anti-inflammatory drugs in the pathogenesis of renal damage. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs: Advances in Inflammation Research, Vol. 6. New York: Raven Press; 1984:148–59.

    Google Scholar 

  21. Crowshaw K. Recent studies on the comparative nephrotoxicity of anti-inflammatory agents. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs 2: Studies in Major Organ Systems. Lancaster: MTP Press; 1987:357–66.

    Google Scholar 

  22. Kimberly RP. Anti-inflammatory drugs and the kidney in systemic lupus erythematosus and other arthropathies: ‘Set-point’ modulation of renal function. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs: Advances in Inflammation Research, Vol. 6. New York: Raven Press; 1984:119–28.

    Google Scholar 

  23. Wiseman EH, Reinert H. Anti-inflammatory drugs and renal papillary necrosis. Agents Actions. 1975;5:322–5.

    Article  PubMed  CAS  Google Scholar 

  24. Guess HA, West R, Strand LM et al. Hospitalizations for renal impairment among users and non-users of non-steroidal anti-inflammatory drugs in Saskatchewan, Canada, 1983. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs, Vol. 2. Lancaster: MTP Press Ltd; 1987:2367–75.

    Google Scholar 

  25. Prescott LF, Martin U. Current status of nephrotoxicity caused by non-steroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs 3, Inflammation and Drug Therapy Series, Vol. V. Dordrecht: Kluwer Academic Publishers; 1992:223–5.

    Google Scholar 

  26. Prescott LF. Renal damage in man from ingestion of anti-inflammatory and analgesic drugs. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-inflammatory Drugs, Advances in Inflammation Research, Vol. 6. New York: Raven Press; 1984:109–17.

    Google Scholar 

  27. Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. J Am Med Assoc. 1990;264:471–5.

    Article  CAS  Google Scholar 

  28. Mavrikakis ME, Georgilis KA, Ziroyannis PN, Kehayoglou KA, Moulopoulos SD. Piroxicam-induced acute renal failure (anuria). Ann Rheum Dis. 1985;44:356.

    Article  PubMed  CAS  Google Scholar 

  29. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med. 1990;112:568–76.

    PubMed  CAS  Google Scholar 

  30. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993;90:11693–7.

    Article  PubMed  CAS  Google Scholar 

  31. De Witt DL, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med. 1993;95(Suppl 2A):40S-5S.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr Karl Thomae GmbH, Birkendorfer Strasse 65, D-88397, Biberach an der Riss, Germany

    H. A. Lehmann, M. Baumeister, L. Lützen & J. Wiegleb

Authors
  1. H. A. Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Baumeister
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Lützen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Wiegleb
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lehmann, H.A., Baumeister, M., Lützen, L. et al. Meloxicam: A toxicology overview. Inflammopharmacology 4, 105–123 (1996). https://doi.org/10.1007/BF02735465

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02735465

Keywords

Search

Navigation